Navigation Links
MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009
Date:1/7/2009

ompany currently markets the Keflex brand of cephalexin and has received regulatory approval for Moxatag - the first and only once-daily amoxicillin product approved for marketing in the U.S. For more information about MiddleBrook, please visit www.middlebrookpharma.com.

About Moxatag:

Moxatag (amoxicillin extended-release) Tablets, 775mg, is a once-a-day extended-release formulation of amoxicillin for oral administration consisting of three components: one immediate-release component and two delayed-release components. The three components of Moxatag are combined in a specific ratio to prolong the release of amoxicillin compared to immediate-release amoxicillin. Moxatag is intended to provide a lower treatment dose, once- daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and older with tonsillitis and/or pharyngitis. For more information about Moxatag, please visit www.middlebrookpharma.com.

Forward-Looking Statements:

This announcement contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933, that involve risks and uncertainties. In some cases, forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "potential, " "estimate, " "will," "may," "predict," "should, " "could, " "would" and similar expressions. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this announcement. All of these forward-looking statements are based on information available to us at this time. Actual results could differ from those projected in these forward-looking statements as a result of many factors, i
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
3. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
4. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
5. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
6. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
7. MiddleBrook to Webcast Management Presentation at the 10th Annual Rodman & Renshaw Healthcare Conference
8. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
9. MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates
10. MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents
11. MiddleBrook Pharmaceuticals Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Washington (PRWEB) June 19, 2013 ... physicians deem it medically necessary, according to a ... and Child Health Journal. The results of this ... for more than a decade – that trying-to-conceive ... and maintaining a healthy body weight. Fairhaven Health ...
(Date:6/19/2013)... the brink of extinction but can we finish the ... a Bristol academic addresses in his new book, published next ... University of Bristol, has produced the first comprehensive history of ... of polio explores the experiences of victims alongside the medical ... , According to a review by The Lancet ...
(Date:6/19/2013)... MA (PRWEB) June 19, 2013 ... , a premier kids entertainment media organization, and ... serious games company, will be introducing the Games ... StudenTopia. The 3D game is geared toward students ... eating and active lifestyles by rewarding positive choices. ...
(Date:6/19/2013)... 19, 2013 The US Food and Drug ... ultra cohesive gel breast implant, Mentor Worldwide’s MemoryShape™. , The ... February 2013. The FDA announced the approval of the MemoryShape™ ... primary augmentations in women 22 years old or ... , The FDA’s approval comes after six years of ...
(Date:6/19/2013)... Loyola University Chicago Niehoff School of Nursing researcher has ... Vitamin D can improve mood in women with diabetes ... whether vitamin D supplementation can reduce blood pressure and ... is from the National Institute of Nursing Research at ... M. Penckofer, PhD, RN and colleagues hypothesize that women ...
Breaking Medicine News(10 mins):Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4Health News:Paralysed with fear: The story of polio 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 3Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 4Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 5Health News:FDA Approved Mentor® MemoryShape™ Breast Implants Now Offered to Patients at Swan Center for Plastic Surgery 2Health News:Loyola receives $1.5 million grant to study vitamin D for diabetes and depression 2
... 1 issue of the journal Sleep indicates that ... remain vigilant and attentive deteriorated significantly after losing less than ... study suggests that even moderate reductions in sleep duration can ... the academic performance of children with ADHD. Results of ...
... This release is also available in Chinese on ... Despite the absence of Medicare coverage, hospital use of computed ... the rise, according to a study in the March issue of ... www.jacr.org ). Colorectal cancer is the second leading cause of ...
... dissection, the current standard surgical treatment for localized non-small ... stage cases , according to a study published in the ... (JTO), the official journal of the International Association for the ... is very low in early-stage cancers with a maximum standard ...
... adhesive patches is at the center of an agreement ... arm of Italian pharmaceutical leader Zambon Co., SpA, to ... ways to deliver oral medications directly to a targeted ... sponsored research agreement between Zcube and UCSF, but is ...
... By Serena Gordon HealthDay Reporter , MONDAY, ... fears soaring as quickly as a child,s rapidly rising temperature. ... Pediatrics (AAP) attempts to allay those fears by reminding parents ... against illness, and that lowering a fever may actually prolong ...
... , MONDAY, Feb. 28 (HealthDay News) -- Many American women ... treatment was tied to higher breast cancer risk. A sharp ... after. However, a new study suggests that the 2002-2003 ... continue through 2007. The data suggests that the drop ...
Cached Medicine News:Health News:Moderate sleep loss impairs vigilance and sustained attention in children with ADHD 2Health News:Moderate sleep loss impairs vigilance and sustained attention in children with ADHD 3Health News:Hospital use of virtual colonoscopy is on the rise, study suggests 2Health News:Lymph node dissection is not essential in small screen-detected lung cancers, new research shows 2Health News:UCSF collaborates with Zcube to develop new ways to deliver drugs 2Health News:Kids' Fevers May Not Always Need Treatment 2Health News:Kids' Fevers May Not Always Need Treatment 3Health News:Drop in Breast Cancer Among White Women May Have Stalled 2
(Date:6/19/2013)... Today MedeAnalytics, a leading provider of ... its Employer Group and Individual Business Analytics ... their employer groups an intuitive and insightful view ... drug claims, network utilization, and overall financial impact. ... "Employer Group and Individual Business Analytics ...
(Date:6/19/2013)... 2013  It may seem like an odd pairing: an ... But these were two of the most talked about topics ... Meeting & Expo that just convened in San ... by some of the top internal medicine experts in the ... research that can not only save lives, but help people ...
(Date:6/18/2013)... -- Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT ), a ... commercialization of novel bile acid therapeutics to treat chronic ... public offering of 1,730,000 shares of its common stock ... In addition, Intercept has granted the underwriters a 30-day ... of common stock. All of the shares ...
Breaking Medicine Technology:MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... Cempra Pharmaceuticals, a developer of differentiated antibiotics, ... (IV) solithromycin demonstrates excellent tolerability and ... up to 800 mg.  Oral administration of solithromycin ... 1 studies.  The presentation will be at the ...
... Covance Inc. (NYSE: CVD ) today announced that ... Tuesday, May 10, 2011 at 3:00 p.m. ET.  Investors may ... .  In order to register and download any necessary software, ... headquarters in Princeton, New Jersey, is one of the world,s ...
Cached Medicine Technology:Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 3Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 4Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 5Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 6Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 7Covance to Present at Baird's 2011 Growth Stock Conference 2
Worn by many professional athletes, EpiTrain is our most popular elbow support....
... combines the therapeutic benefits of controlled compression ... to minimize pain. The cuff is anatomically ... maximum cryotherapy. The Elbow Cryo/Cuff is available ... a pediatric size.,All Cryo/Cuffs can be ordered ...
... The Cryo/Cuff for Walking Brace is designed ... to the Aircast PneumaticWalker™ (sold separately). When ... cold water, the cuff surrounds the foot ... to minimize hemarthrosis, swelling, and pain.,All Cryo/Cuffs ...
... support helps reduce swelling and minimize pain while ... easy to apply - it slips on like ... into shoes. It features bilateral spiral stays ... support and stability. This is an excellent ...
Medicine Products: